NewSpring Capital / NewSpring Healthcare
NewSpring Capital and Kineticos lead Kincell Bio financing
Summary: Kincell Bio announced a $22 million financing led by NewSpring Capital through NewSpring Healthcare and existing investor Kineticos Life Sciences. The Kincell source also says Pete Buzy, former President and CEO of Catalent Cell & Gene Therapy, joined Kincell Bio's board.
Why it matters: The update may matter to due-diligence readers as a public NewSpring healthcare-strategy activity signal, while the source should not be used to infer Kincell valuation, ownership, manufacturing quality, fund exposure, returns, or investment merit.
Summary
Kincell Bio announced that it completed a $22 million financing led by NewSpring Capital through NewSpring Healthcare and existing investor Kineticos Life Sciences. The Kincell source says proceeds were expected to support cGMP expansion, process-development services, and solutions for emerging cell-therapy companies.
The same announcement says Pete Buzy, former President and CEO of Catalent Cell & Gene Therapy, was appointed to Kincell Bio’s board. This draft treats the item as dated May 2025 seed/backfill coverage from a portfolio-company source, not as current August 2026 news or as evidence of fund-level exposure, company quality, valuation, ownership, returns, or investment merit.
Why it matters
For due-diligence readers, the useful signal is that NewSpring is publicly named in a healthcare and life-sciences financing with a board appointment and operating-expansion use case. Manager-specific portfolio-company announcements can help readers track strategy activity, sector focus, named co-investors, and the kinds of operational themes a manager is willing to associate with publicly.
The signal is narrow. Kincell’s release supports the financing amount, NewSpring Healthcare lead role, Kineticos co-lead role, board appointment, and stated use of proceeds. It does not establish Kincell’s valuation, ownership split, clinical or manufacturing quality, customer demand, fund-level economics, realized or expected returns, or suitability for any investor.
Source notes
- Kincell Bio source-party announcement: https://kincellbio.com/newspring-capital-and-kineticos-life-sciences-lead-22-million-investment-in-cell-therapy-cdmo-kincell-bio-appoints-industry-veteran-pete-buzy-to-board-of-directors/
- Source posture: primary portfolio-company announcement, suitable for source-attributed facts about the May 15, 2025 date, $22 million financing, NewSpring Capital/NewSpring Healthcare role, Kineticos Life Sciences role, Pete Buzy board appointment, cGMP/process-development use-of-proceeds framing, and NewSpring firm boilerplate.
- Verifier posture: the 2026-08-13 PM source reviewer recovered body-level support from Kincell’s official domain and reported no same-event local post or draft at the time of review.
- Editorial caveat: this is dated backfill and is portfolio-company-centered. Keep company, market, manufacturing, and expansion claims attributed to Kincell and avoid treating the announcement as independent validation of Kincell or NewSpring.
9AT filing context
Public adviser/profile context reviewed by 9AT maps NewSpring Capital to CRD 160608 / SEC file 801-73849, with Radnor, Pennsylvania adviser identity, public domain newspringcapital.com, and about $3.3 billion in reported ADV regulatory AUM/profile scale. That context is useful only as broad adviser/platform identity background.
Prior public filing-derived context also identified NewSpring Health private-fund names under NewSpring’s adviser file, including NewSpring Health Capital IV, NewSpring Health Capital III, and related NewSpring Health Capital names. Those names can support broad healthcare-strategy background only; they should not be used to state that any specific fund invested in Kincell unless a public source says so.
No 13F or Form 5500 context is included. The analyst handoff reported no public 13F filer for NewSpring in this pass, and employee-benefit-plan filings do not add useful context to this private healthcare financing announcement.
What to watch
Watch for later Kincell, NewSpring, Kineticos, or transaction-party disclosures that clarify the exact NewSpring vehicle, closing mechanics, governance, additional financing, manufacturing capacity, or customer and regulatory milestones.
Future coverage should continue to separate source-attributed operating claims from filing-derived adviser identity context. It should not infer fund exposure, transaction economics, clinical outcomes, manufacturing quality, customer adoption, or investment merit from this financing announcement alone.